Tue, April 30, 2024

Matthew Caufield Initiated (ADVM) at Strong Buy and Held Target at $30 on, Apr 30th, 2024

Matthew Caufield of HC Wainwright & Co., Initiated "Adverum Biotechnologies, Inc." (ADVM) at Strong Buy and Held Target at $30 on, Apr 30th, 2024.

Matthew has made no other calls on ADVM in the last 4 months.



There are 3 other peers that have a rating on ADVM. Out of the 3 peers that are also analyzing ADVM, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Luca Issi of "RBC Capital" Maintained at Hold with Decreased Target to $20 on, Tuesday, March 19th, 2024


These are the ratings of the 2 analyists that currently disagree with Matthew


  • Graig Suvannavejh of "Mizuho" Maintained at Strong Buy with Decreased Target to $22 on, Monday, April 29th, 2024
  • Daniil Gataulin of "Chardan Capital" Reiterated at Strong Buy with Increased Target to $40 on, Tuesday, March 19th, 2024